DAYBUE trofinetide Updated Nov 6
DAYBUE is already approved and generating strong commercial revenue. The next catalyst for this specific drug is the planned Japan regulatory filing in 2027, which could support a 2028 launch, but no hard date is set. Watch quarterly DAYBUE sales growth trajectory and European launch uptake (Germany launched October 2026) as the key near-term value drivers for ACAD stock.
- DAYBUE is the first and only FDA-approved treatment for Rett syndrome, a rare neurodevelopmental disorder with no direct approved competitors, giving it a market monopoly.
- Q3 2026 DAYBUE net sales surged 39% year-over-year, leading ACAD to raise full-year 2026 guidance to $505-$520 million.
- European Commission approved DAYBU (trofinetide) on August 24, 2026, opening a new geographic market; Germany launched in October 2026.
- UBS downgraded ACAD from Buy to Neutral in October 2026, reflecting concerns about growth trajectory or valuation.
- CFO Mark Schneyer sold $69,342 worth of shares on October 30, 2026 at $20.88, a bearish insider signal.
- The EMA initially refused marketing authorization for Daybu in February 2026 before granting a restricted indication after re-examination, highlighting regulatory risk in new markets.